# Format of report on Corporate Governance to be submitted by listed entity on quarterly basis

 Name of Listed Entity
 Quarter ending : Ajanta Pharma Limited : 31st March 2020

I. Con	I. Composition of Board of Directors											
С	Name of the	PAN\$	Category	Initial Date	Date of Re-	Date of	Tenure	Date of	No of	No of	Number of	No of post
	Director	& DIN	(Chairperson	of	appoint	Cessation	*	Birth	Directo	Indepen	membershi	of
			/Executive/	Appointme	ment				rship in	dent	ps in Audit/	Chairperso
			Non-	nt					listed	Director	Stakeholder	n in Audit/
			Executive/						entitie	s in	Committee	Stakeholde
			independent						S	listed	(s)	r
			1						includi	entities	including	Committee
			Nominee) <sup>&amp;</sup>						ng this	includin	this listed	held in
									listed	g this	entity	listed
									entity	listed	(Refer	entities
									(in	entity	Regulation	including
									refere	[in	26(1) of	this listed
									nce to	referenc	Listing	entity
									Regula	e to	Regulations	(Refer
									tion	proviso	)	Regulation
									17A (1)	to		26(1) of
										regulati		Listing
										on 17A		Regulations
										(1)]		)
	SAME AS PREVIOUS QUARTER											

II. Composition of Committees									
Name of Committee	Whether Regular chairperson appointed	Name of Committee members	Category (Chairperson/Executive/Non Executive/Independent/Nominee)\$	Date of Appointment	Date Cessation	of			
SAME AS PREVIOUS QUARTER									

III. Meeting of Board of Directors									
Date(s) of Meeting (if	Date(s) of Meeting (if	Whether requirement	Number of	Number of Independent	Maximum gap between any two				
any) in the previous any) in the relevant		of Quorum met*	Directors	directors present *	consecutive (in number of days)				
quarter	quarter		present *						
5 <sup>th</sup> November 2019	5 <sup>th</sup> February 2020	Yes	8	4	91				
* to be filled in only for	* to be filled in only for the current quarter meetings								
IV. Meeting of Committees									
Date(s) of meeting of	Date(s) of meeting of the Whether requirement Number of Number of Date(s) of meeting of the Maximum gap between any t								
committee in the rele	evant of Quorum met*	Directors Ir	ndependent	committee in the	consecutive meetings in number				
quarter		present * d	irectors present *	previous quarter	of days*				
5 <sup>th</sup> February 2020	Yes	4 3		5 <sup>th</sup> November 2019	91				
* This information has to be mandatorily be given for audit committee, for rest of the committee giving this information is optional									

	* This information has to be mandatorily be given	for audit committee,	for rest of the committee	giving this information	is optional
ı	**to be filled in only for the current quarter meet:	ings			

V. Related Party Transactions					
Compliance status (Yes/No/NA) refer note below					
Yes					
Material RPTs are only with Wholly Owned subsidiary of the Company and o shareholder approval					
is not required for such RPTS as per Regulation 23 (5) the Listing Regulations.					
Yes					

### Note:

- 1. In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.
- 2. If status is "No" details of non-compliance may be given here.

### VI. Affirmations

- 1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2. The composition of the following committees is in terms of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015
  - a. Audit Committee
  - b. Nomination & Remuneration committee
  - c. Stakeholders relationship committee
  - d. Risk management committee (applicable to the top 500 listed entities): Applicable

- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 5. This report will be placed before Board of Directors at the ensuing Board meeting.

Name & Designation: Gaurang Shah

Sd/-

Company Secretary / Compliance Officer / Managing Director / CEO / CFO: Company Secretary & Compliance Officer

 Name of Listed Entity
 Financial Year ending : Ajanta Pharma Limited : 31st March 2020

Item	Compliance status (Yes/No/NA)refer note below		
Details of business	Yes		
Terms and conditions of appointment of indeper	Yes		
Composition of various committees of board of o	directors	Yes	
Code of conduct of board of directors and senior	Yes		
Details of establishment of vigil mechanism/ Wh	Yes		
Criteria of making payments to non-executive d	irectors	Disclosed in Annual Report	
Policy on dealing with related party transactions	5	Yes	
Policy for determining 'material' subsidiaries		Yes	
Details of familiarization programmes imparted	to independent directors	Yes	
Contact information of the designated officials of	of the listed entity who are responsible for	Yes	
assisting and handling investor grievances			
E-mail address for grievance redressal and other	relevant details	Yes	
Financial results	Yes		
Shareholding pattern	Yes		
Details of agreements entered into with the med	None		
New name and the old name of the listed entity		N.A.	
II Annual Affirmations			
Particulars	Regulation Number	Compliance status (Yes/No/NA)refer note below	
Independent director(s) have been appointed in terms of specified criteria of	16(1)(b) & 25(6)	Yes	
'independence' and/or 'eligibility'			
Board composition	17(1)	Yes	
Meeting of Board of directors	17(2)	Yes	
Review of Compliance Reports	17(3)	Yes	
Plans for orderly succession for appointments	Yes		
Code of Conduct	17(4) 17(5)	Yes	
Fees/compensation	17(6)	Yes	
Minimum Information	17(7)	Yes	
Compliance Certificate	17(8)	Yes	
Risk Assessment & Management	17(9)	Yes	

Performance Evaluation of Independent	17(10)	Yes
Directors	17(10)	163
Composition of Audit Committee	18(1)	Yes
Meeting of Audit Committee	18(2)	Yes
Composition of nomination & remuneration	19(1) & (2)	Yes
committee	19(1) & (2)	ies
Composition of Stakeholder Relationship	20(1) & (2)	Yes
Committee Stakeholder Relationship	20(1) & (2)	ies
Composition and role of risk management	21(1) (2) (2) (4)	Yes
committee	21(1),(2),(3),(4)	ies
Vigil Mechanism	22	Yes
Policy for related party Transaction	23(1),(5),(6),(7) & (8)	Yes
Prior or Omnibus approval of Audit Committee	23(2), (3)	Yes
for all related party transactions	22/4)	No material related ments to constitute
Approval for material related party	23(4)	No material related party transactions, save
transactions	24(4)	and except with wholly owned subsidiary
Composition of Board of Directors of unlisted	24(1)	There are no material subsidiaries
material Subsidiary		0.4(0) (2) 6 (4) 14
Other Corporate Governance requirements	24(2),(3),(4),(5) & (6)	24(2),(3) & (4) - Yes
with respect to subsidiary of listed entity		24(5) & (6) - N.A.
Maximum Directorship & Tenure	25(1) & (2)	Yes
Meeting of independent directors	25(3) & (4)	Yes
Familiarization of independent directors	25(7)	Yes
Memberships in Committees	26(1)	Yes
Affirmation with compliance to code of	26(3)	Yes
conduct from members of Board of Directors		
and Senior management personnel		
Disclosure of Shareholding by Non-Executive	26(4)	Yes
Directors		
Policy with respect to Obligations of directors	26(2) & 26(5)	Yes
and senior management		
Note		

### Note

<sup>1</sup> In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.

2 If status is "No" details of non-compliance may be given here.

3 If the Listed Entity would like to provide any other information the same may be indicated here.

## III Affirmations:

The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied.

Name & Designation : Gaurang Shah

Sd/-

Company Secretary / Compliance Officer / Managing Director / CEO: Company Secretary & Compliance Officer